

## Curis to Present at Upcoming Investor Conferences

LEXINGTON, Mass., Nov. 26, 2014 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers, today announced that the Company will present at the following upcoming conferences:

**Piper Jaffray 26<sup>th</sup> Annual Healthcare Conference**, Wednesday, December 3, 2014 at 4:00 p.m. ET. A corresponding webcast of this presentation can be accessed by visiting:

<http://www.media-server.com/m/p/9gjweur8>

**Oppenheimer 25<sup>th</sup> Annual Healthcare Conference**, Thursday, December 11, 2014 at 2:45 p.m. ET. A corresponding webcast of this presentation can be accessed by visiting:

<http://www.veracast.com/webcasts/opco/healthcare2014/27211450115.cfm>

Dr. Ali Fattaey, President and Chief Executive Officer, will provide an overview of Curis' pipeline including CUDC-907, a dual histone deacetylase (HDAC) and phosphoinositide 3-kinase (PI3K) inhibitor, CUDC-427, an antagonist of inhibitor of apoptosis (IAP) proteins and Debio 0932, an oral HSP90 inhibitor. Dr. Fattaey will also provide an overview on Erivedge® (vismodegib), a hedgehog pathway inhibitor developed under collaboration with Genentech and Roche that is the only approved medicine for patients with advanced basal cell carcinoma.

The presentations will be archived shortly after the live events and available for 30 days following each conference, and also available for 30 days on the Investor Relations section of the Curis website at [www.curis.com](http://www.curis.com).

### About Curis, Inc.

Curis is an oncology-focused biotechnology company developing novel drug candidates for the treatment of human cancers. Curis' pipeline of drug candidates includes CUDC-907, a dual HDAC and PI3K inhibitor, CUDC-427, a small molecule antagonist of IAP proteins and Debio 0932, an oral HSP90 inhibitor. Curis is also engaged in a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge®, the first and only FDA-approved medicine for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at [www.curis.com](http://www.curis.com).

CONTACT: For More Information:

Mani Mohindru, Ph.D.

Vice President, Corporate Strategy and Investor Relations

Curis, Inc.

617-503-6605

[mmohindru@curis.com](mailto:mmohindru@curis.com)

Michael P. Gray

Chief Business and Financial Officer

Curis, Inc.

617-503-6632

[mgray@curis.com](mailto:mgray@curis.com)

---

<https://investors.curis.com/Curis-to-Present-at-Upcoming-Investor-Conferences>